Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegilodecakin + FOLFOX in Metastatic Pancreatic Cancer
NCT02923921Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Cytokines & Interferons
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of ilodecakin (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival at 30 months. Started Mar 2017; status: completed.
02
Drugs
ilodecakin
Beyond the preview
Go deeper on NCT02923921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923921.